The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

The proposed Human Genome Project II could set in motion a ‘paradigm shift’ toward more precise public health, and a global ...

A postal voting center has been established for three days at Srinagar Gandhi Memorial College for all eligible voters employed in essential services followi ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Neste Oyj (Porvoo, Finland; ITOCHU Corp. (Tokyo; and GS Caltex (Seoul, South Korea; have collaborated to make the first ...

It is the last week of campaigning before the second phase of the Jammu and Kashmir Assembly elections takes place on October ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

Shares in Novo Nordisk (NYSE: NVO) fell more than 4% following the market open on Friday after the Danish pharma giant released data from a phase 2a clinical trial with its obesit ...

K92 Mining aims to increase gold production from 120,000 toz to 450,000 toz by 2026. Discover more on KNTNF stock here.